Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : TP-1287 is an investigational oral phosphate prodrug of the CDK9 inhibitor alvocidib. This prevents productive transcription and causes reduction of mRNA in genes (c-MYC and MCL-1) transcription leading in tumor cell apoptosis.
Brand Name : TP-1287
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 10, 2023
Details : TP-1287 is enzymatically cleaved, yielding active moiety, potent inhibitor of CDK9. Inhibiting CDK9 is thought to downregulate transcription of target genes, including MCL-1, reducing leukemic blast viability in MCL-1–dependent hematologic malignancies...
Brand Name : TP-1287
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 08, 2022
Details : These data, highlighting a novel biomarker detection method for CDK9 inhibition and evaluating the anti-tumor activity of alvocidib and TP-1287 in hematologic cancer cells, are being presented at the American Association for Cancer Research (AACR) Virtua...
Brand Name : TP-1287
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 22, 2020
Details : Preliminary findings from a Phase 1, first-in-human, dose escalation study of TP-1287 showed clinical activity and a tolerable safety profile as a monotherapy in patients with heavily pretreated, relapsed and refractory solid tumors.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 29, 2020
LOOKING FOR A SUPPLIER?